Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Administration Video
This video will take you through the process of preparing and administering Vocabria▼ + Rekambys▼
Dovato (dolutegravir/lamivudine) is now available in Ireland for the treatment of HIV-1 in adults and adolescents above 12 years of age weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.3
DOVATO (dolutegravir/lamivudine)
Summary of product characteristics
Patient Information Leaflet
Vocabria▼ (cabotegravir) injection is indicated, in combination with Rekambys▼ (rilpivirine) injection, for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/ mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class.4
VOCABRIA ▼ (cabotegravir) +
REKAMBYS ▼ (rilpivirine)
Abbreviated Prescribing Information
Vocabria Patient Information Leaflet
Rekambys Patient Information Leaflet
References
- Montaner JS, Wood E, Kerr T et al. Expanded highly active antiretroviral therapy coverage among HIV-positive drug users to improve individual and public health outcomes. J Acquir Immune Defic Syndro. 2010;55 Suppl. 1:5
- Eisinger RW, Dieffenbach CW, Fauci AS. HIV VIral Load and Transmissibility of HIV Infection: Undetectable Equals Untransmittable. JAMA. 2019;321(5):451-452.
- Dovato Summary of Characteristics. Available at https://www.medicines.ie/medicines/dovato-50-mg-300-mg-film-coated-tablets-34871/spc. Last accessed: February 2024
- Vocabria Summary of Characteristics. Available at https://www.medicines.ie/medicines/vocabria-600-mg-prolonged-release-suspension-for-injection-35220/spc Last accessed: February 2024
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information.
Healthcare professionals are asked to report any suspected adverse reactions.
REKAMBYS (rilpivirine long acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under licence by the ViiV Healthcare group of companies.
All other trademarks are owned by the ViiV Healthcare group, or its licensor.
©2024 GSK group of companies. All rights reserved.
Date of Preparation: February 2024 PM-IE-HVX-WCNT-200003
